Drug intelligence / Profile preview

venom desensitisation + Advax

Development stage: Unknown
Lead developer: Vaxine
Modality: Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

Venom desensitisation + Advax is an adjuvanted allergy immunotherapy vaccine being developed by Vaxine for the treatment of insect venom allergy, specifically targeting bee and ant venom. The formulation combines venom allergens with Vaxine's proprietary Advax adjuvant, which is based on delta-inulin. The mechanism of action involves inducing immune tolerance and stimulating the production of protective IgG blocking antibodies, which compete with IgE for allergen binding, thereby reducing the allergic response upon subsequent exposure to venom. It is currently in Phase 1 clinical development.

Other names: bee/ant venom allergy immunotherapyvenom immunotherapy + Advax

Targets

Honey bee venom allergensMyrmecia pilosula venom allergens

Beyond the preview

Go deeper on venom desensitisation + Advax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on venom desensitisation + Advax.